Sandoz Egypt Pharma, a division of the Novartis Group, and Ibnsina Pharma, a pharmaceutical distribution company, have partnered to expand access to Sandoz’s over-the-counter (OTC) portfolio of products through a distribution and promotion agreement. The goal of this agreement is to extend Sandoz Egypt Pharma’s reach to more patients by leveraging Ibnsina’s extensive network throughout the country.
Sandoz’s OTC product line, which was introduced in Egypt in early 2022, offers a range of non-prescription products to treat various health conditions, including gastrointestinal diseases, pain management, respiratory issues, and paediatric vitamins and supplements.
This partnership aims to not only increase access to these products and enhance the healthcare system, but also bring together the companies’ expertise to educate pharmacists and provide them with science-based information to better serve their customers.
Reham Soliman, Head of Legal NEA at Sandoz Egypt Pharma leads the legal team.